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Background. Erythrocyte Duffy blood group negativity reaches fixation in African populations where Plasmodium vivax (Pv) is
uncommon. While it is known that Duffy-negative individuals are highly resistant to Pv erythrocyte infection, little is known
regarding Pv susceptibility among heterozygous carriers of a Duffy-negative allele (+/2). Our limited knowledge of the
selective advantages or disadvantages associated with this genotype constrains our understanding of the effect that
interventions against Pv may have on the health of people living in malaria-endemic regions. Methods and Findings. We
conducted cross-sectional malaria prevalence surveys in Papua New Guinea (PNG), where we have previously identified a new
Duffy-negative allele among individuals living in a region endemic for all four human malaria parasite species. We evaluated
infection status by conventional blood smear light microscopy and semi-quantitative PCR-based strategies. Analysis of
a longitudinal cohort constructed from our surveys showed that Duffy heterozygous (+/2) individuals were protected from Pv
erythrocyte infection compared to those homozygous for wild-type alleles (+/+) (log-rank tests: LM, p=0.049; PCR, p=0.065).
Evaluation of Pv parasitemia, determined by semi-quantitative PCR-based methods, was significantly lower in Duffy +/2 vs. +/+
individuals (Mann-Whitney U: p=0.023). Overall, we observed no association between susceptibility to P. falciparum
erythrocyte infection and Duffy genotype. Conclusions. Our findings provide the first evidence that Duffy-negative
heterozygosity reduces erythrocyte susceptibility to Pv infection. As this reduction was not associated with greater
susceptibility to Pf malaria, our in vivo observations provide evidence that Pv-targeted control measures can be developed
safely.
Citation: Kasehagen LJ, Mueller I, Kiniboro B, Bockarie MJ, Reeder JC, et al (2007) Reduced Plasmodium vivax Erythrocyte Infection in PNG Duffy-
Negative Heterozygotes. PLoS ONE 2(3): e336. doi:10.1371/journal.pone.0000336
INTRODUCTION
In PNG, malaria is caused by P. vivax (Pv), P. falciparum (Pf), P.
malariae (Pm) and P. ovale (Po), and endemic in regions below
1600 meters elevation [1]. Individual infections with multiple
Plasmodium species (mixed infections) are common, and there is
growing interest in the potential that cross-species regulatory
mechanisms control parasitemia and malarial disease [2–5].
Ministry of Health statistics show that malaria represents the
most significant public health burden in PNG [6]. Moreover the
overlapping occurrence of erythrocyte polymorphisms in malar-
ious regions of PNG [7–10] suggests that malaria exerts significant
selective pressure on the human population as proposed for other
malaria-endemic regions of the world [11]. In large part it is
presumed that selective pressure by malaria is associated with Pf
because high rates of severe falciparum malaria mortality are
observed in Africa. Although the selective burden attributable to
Pv has been more difficult to substantiate, recent studies have
shown evidence for severe vivax malaria [12,13]. A convergence of
human genetics and Plasmodium species interactions observed pre-
viously in Vanuatu led Williams et al. [14] to the controversial
hypothesis that a
+-thalassemia predisposes young children to Pv
infection and that early exposure to this more ‘‘benign’’ species
reduced the risk of severe falciparum malaria. Under this
hypothesis host genetic adaptations that reduce the risk of Pv
would not be favored to arise in regions that were co-endemic for
Pf.
It was surprising then that our earlier studies in PNG discovered
the same single nucleotide polymorphism (SNP) in the Duffy gene
promoter observed on the African Duffy negative FY*B
null (B2)
allele on the FY*A allele [15] in a Melanesian population experi-
encing year-round hyperendemic exposure to both Pv and Pf [16]
(Duffy nomenclature summarized in Methods). In our original
study, we identified 23 heterozygous carriers of this FY*A
null allele
(A2) and no homozygous negative (A2/A2) individuals [15].
Duffy antigen expression on erythrocytes from A+/A2 individuals
was reduced by 50% compared to levels expressed on erythrocytes
from A+/A+ individuals [15]. In in vitro assays, erythrocytes from
A+/A2 donors (compared to A+/A+ donors) formed significantly
fewer rosettes when mixed with COS-7 cell transfectants expres-
sing the Pv Duffy binding protein [17]. These preliminary findings
suggested that reduced expression of the Duffy blood group
antigen on red blood cells would decrease susceptibility to Pv
blood-stage infection. Here, through multiple epidemiologic
surveys evaluating malaria infection status at different time-points,
we present evidence that the Duffy A+/A2 genotype is associated
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METHODS
Study design and human subjects
We conducted two sets of serial cross-sectional surveys to estimate
malaria prevalence in the Wosera, East Sepik Province, Papua
New Guinea. The first set of seven prevalence surveys was
conducted monthly from July 1998 to January 1999 in six villages
in the Wosera (cumulative population 1845), where the Papua
New Guinea Institute of Medical Research (PNGIMR) has
performed numerous malaria epidemiologic surveys [16]. Partic-
ipation was voluntary and village residents were free to choose
when or if they participated in a survey. During the survey period,
1,689 (91.5%) residents from the six villages participated in at least
one blood draw; 6,752 blood samples were collected. From these
surveys, we constructed a longitudinal cohort of 467 children
(2531 observations) who were under 15 years of age and who had
attended four or more of the monthly malaria prevalence surveys.
To control for the potential confounding effects of age, sex, and
village of residence, we matched 11 children (58 observations) who
were A+/A2 with 33 children (167 observations) who were A+/
A+ in a ratio of 1:3 on these characteristics.
A second set of four malaria prevalence surveys was conducted
at approximately 6-month intervals from August 2001 to June
2003 in 29 villages of the Wosera [18]. At the completion of these
serial cross-sectional surveys, 8,793 (approximately 67.6%) resi-
dents participated in at least one blood draw; 16,209 blood
samples were collected [18]. In each set of cross-sectional surveys,
we compared susceptibility to Pv and other Plasmodium species
blood-stage infections to Duffy genotype.
Ethical approval for these studies and procedures for oral/written
informed consent were obtained from the Medical Research and
Advisory Council of Papua New Guinea, the Institutional Review
Board for Human Investigation of Case Western Reserve University
and University Hospitals of Cleveland, OH, and the National
Institute of Allergy and Infectious Diseases, International Clinical
Studies Review Committee (ICSRC).
Sample collection and DNA extraction
Samples were collected in K
+-EDTA Vacutainer
TM tubes, and
stored at 220uC until DNA extraction could be performed. DNA
was extracted from whole blood (200 mL) using QIAamp 96 spin
blood kits (QIAGEN, Valencia, CA).
Malaria Diagnosis
Thick/thin smears were prepared by standard procedures, stained
with 4% Giemsa and examined by PNGIMR-trained micro-
scopists under oil-immersion (1006). Parasite species and species-
specific densities were identified and recorded while counting the
number of microscope fields containing 200 leukocytes as
described previously [16]. Conformational diagnosis of all four
human Plasmodium parasite species was performed by a post-PCR
ligase detection reaction/fluroescent microsphere assay (LDR-
FMA) [19,18,20]. Finally, we performed real-time quantitative
PCR (RTQ-PCR) analysis of Pv blood-stage infection by methods
described previously [21].
Duffy (FY) nomenclature
A single nucleotide polymorphism (SNP) in the Duffy gene (FY)
corrupts the GATA-1 transcription factor binding site regulating
erythroid Duffy antigen expression specifically (233 TRC [22];
numbering based on Iwamoto et al., 1996 [23]). A second SNP
responsible for a glycine (G) to aspartic acid (D) substitution [24] at
amino acid 42 underlies Fy
a and Fy
b antigenic variation.
Combinations of these two SNP lead to FY*A (A+), FY*A
null
(A2), FY*B (B+) and FY*B
null (B2) alleles [25].
PCR-based Genotyping
A 329 bp fragment inclusive of the GATA-1 SNP in the FY gene
was PCR amplified as previously described [15] using an upstream
primer FY277(+)5 9-CAGGAAGACCCAAGGCCAG-39, and
downstream primer FY605(2)5 9-CCATGGCACCGTTTGGT-
TCAGG-39; two-step thermocycling conditions 30 seconds at
94uC and 45 seconds at 68uC were repeated for 40 cycles.
Restriction fragment length polymorphism (RFLP) was used to
distinguish between the 77 bp FY+ (233T) and 65 bp FY2 (233C)
allelic fragments using the restriction endonuclease StyI following
recommended protocol (New England BioLabs, Beverly, MA).
Restriction fragments were separated by electrophoresis on 4%
1xTBE agarose gels (5:1 GTG:NuSieve:LE, FMC BioProducts,
Rockland, ME), stained with a 1:10,000 dilution of SYBRH Gold
(Molecular Probes, Eugene, OR), and visualized on a StormH 860
Scanner (Molecular Dynamics, Sunnyvale, CA). Genotyping
assays for the FYA vs FYB SNP [15], the 27 bp deletion in
erythrocyte membrane protein band 3 (SLC4A1D27) [9], the
glycophorin C exon 3 deletion (GYPCDex3) [9] underlying Gerbich
negativity, and the a-globin deletions [26] associated with
a2thalassemia were performed using methods previously de-
scribed.
Statistical Analysis
The primary aim of the analysis was to compare the susceptibility
to Pv blood-stage infection according to Duffy genotype. Further
analyses compared susceptibility to all other Plasmodium species by
Duffy genotype. To address this aim, we compared the incidence
rates of blood-stage infection (estimated as infections per 100
person-months of observation) among children who were A+/A2
with children who were A+/A+ using the rate ratio and 95%
confidence intervals [27]. We estimated the proportion who
escaped blood-stage infection during the observation period using
Kaplan-Meier methods and compared curves using the log-rank
test. To assess the potential effect of correlation between household
members, we calculated the intra-class correlation coefficient [28]
for household infection and found that it was #0.10, indicating
household interdependence did not greatly affect study statistics.
Finally, we evaluated Pv parasite density and mean fluorescent
signal intensity (a measure that correlates with the intensity of Pv
infection) over time in an analysis of repeated measures using
generalized estimating equations [29]. To adjust for potential
confounding effects, we included age, sex, village, and genotype
information as time-independent variables and Pf infection status
and season as time-dependent variables. Final models were
selected using fit as a criterion in a series of iterations [29–31] in
which the correlation matrix and mean distribution were
systematically varied. In the latter surveys, differences in mean
Pv and Pf fluorescent signal intensity between A+/A2 and A+/A+
children were also compared using Mann-Whitney U tests.
We performed all statistical analyses using SASH software (SAS
Institute, version 9.1, Cary, NC).
RESULTS AND DISCUSSION
From surveys conducted since July 1998, our primary objective
was to investigate the relationship between the Duffy A2 allele
and susceptibility to Pv blood-stage infection. For these studies we
Pv in FY(-) Heterozygotes
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Wosera residents (69.9%) to characterize the distribution and
frequency of the A2 allele and investigate whether this new allele
alters susceptibility to Pv and thereby confers some fitness
advantage. We identified 223 Duffy A+/A2 individuals and no
A2/A2 (Duffy-negative) individuals (Duffy A2 allele frequen-
cy=0.012). The distribution of A+/A2 individuals was not
random within the Wosera villages and the proportion of A2
carriers within the villages ranged from 0 to 13.0%. Within the
community, overall infection prevalence by the four human
Plasmodium species parasites in recent surveys was similar to that
reported previously [32], and was observed to vary depending on
diagnostic methodology sensitivity (blood smear light microscopy
[LM], LDR-FMA): Pv–10.4%, 27.1%; Pf–22.3%, 32.9%; Pm–
4.2%, 12.4%; Po–0.2%, 5.5% [18]. Mixed Plasmodium species
infections were observed in 2.4% (LM) or 16.8% (LDR-FMA) of
individuals [18].
Our study setting in PNG is therefore distinct from African
populations. In comparison to vivax-hypoendemic Africa where
Duffy negative (B2/B2) homozygosity predominates and confers
complete resistance to Pv erythrocyte infection, reduced Duffy
erythrocyte antigen expression in PNG heterozygotes (A+/A2)
may significantly reduce natural in vivo susceptibility to blood-stage
Pv infection in vivax-hyperendemic PNG. To test this hypothesis,
we analyzed data from two different epidemiologic studies in the
Wosera.
First, in an unmatched longitudinal cohort analysis (July 1998 to
January 1999), we compared the rate of Pv blood-stage infection in
11 A+/A2 (age range 2 to 13; mean age 8) and 456 A+/A+ (age
range 1 to 14; mean age 7) children under 15 years of age who
attended at least four of the monthly malaria prevalence surveys.
Overall we found that the rate of Pv infection determined by
conventional LM analysis was 52.0% lower in A+/A2 compared
with A+/A+ children (rate ratio=0.48, 95% confidence interval
(CI): 0.24, 0.96; 12.1 vs. 25.2 infections per 100 person months of
observation). When we estimated the proportion of children who
escaped Pv blood-stage infection during the survey period, we
found that a greater proportion of A+/A2 heterozygotes escaped
Pv infection (72.7%) during the 7-month survey compared with
A+/A+ homozygotes (30.6%) (log-rank test, p=0.026; hazard
ratio 0.336, 95% CI: 0.198, 0.901; Figure 1A). Using the same
cohort of children, we also estimated the proportion of children
who escaped Pf blood-stage infection during the survey period and
found no differences between A+/A2 heterozygotes (27.3%) and
A+/A+ homozygotes (22.5%) (log-rank test, p=0.875; hazard
ratio 1.051, 95% CI: 0.471, 2.420; Figure 1B). In the longitudinal
analysis adjusting for Pf co-infection and correlations over time, we
found that children with the A+/A2 genotype had at least a 2-fold
lower mean Pv parasite density based on LM than children with
the A+/A+ genotype, but this difference did not reach statistical
significance (p=0.16).
To adjust for age, sex, and village of residence, we matched 11
A+/A2 with 33 A+/A+ children under 15 years of age (age range
2 to 13.2; mean age 8.3) who attended at least four of the 1998–
1999 cross-sectional malaria prevalence surveys. In a longitudinal
analysis, we observed that A+/A2 compared to A+/A+ was
associated with a risk reduction of 46.0% (rate ratio=0.54, 95%
CI: 0.25, 1.13; 12.1 vs. 22.6 infections per 100 person months of
observation. The proportion of A+/A2 children who escaped Pv
blood-stage infection (72.7%) was greater than the proportion of
A+/A+ children (23.6%) (log-rank test, p=0.049, hazard ratio
0.349, 95% CI: 0.146, 0.995; Figure 2A). Given the widely
recognized challenges encountered in the reproducibility of
malaria LM diagnosis [5], we evaluated each child’s malaria
status at each time point by PCR [20]. By the more sensitive test
we again observed that A+/A2 heterozygotes escaped Pv
erythrocyte infection more successfully (21.8%) than the A+/A+
homozygotes (0%) over the 7-month survey (log-rank test,
p=0.065, hazard ratio 0.531, 95% CI: 0.188, 1.051; Figure 2B).
We also estimated the proportion of children who escaped Pf
blood-stage infection during the monthly prevalence survey period
using data from both LM and PCR-based diagnostic techniques,
we found no differences between A+/A2 heterozygotes (27.3%
LM; 0% PCR) and A+/A+ homozygotes (39.4% LM; 13.6%
PCR) (LM: log-rank test, p=0.675; hazard ratio 1.167, 95% CI:
0.468, 3.225; Figure 2C) (PCR: log-rank test, p=0.453; hazard
ratio 0.836, 95% CI: 0.203, 2.035; Figure 2D).
Recognizing that our observations in the initial set of surveys
were based on a limited number of heterozygous children, we
compared the intensity of Pv infections by age (Figure 3) in a subset
of 467 children from the serial cross-sectional surveys of 29
Wosera villages (August 2001 to June 2003). Here, among children
under 15 years of age, we observed that the mean Pv fluorescent
signal intensity (corresponds with parasitemia [20]) was signifi-
cantly lower among A+/A2 individuals (m=2.37, log10 trans-
formed) compared to A+/A+ individuals (m=2.96) (Mann-
Figure 1. Susceptibility to blood-stage infection during monthly
prevalence surveys (1998–99); unmatched longitudinal analyses.
Diagnosis of Pv and Pf erythrocyte infection was performed by light
microscopy (LM) [16]. Light gray line represents A+/A2 (n=11) and
dark gray line represents A+/A+ (n=453). A, Cumulative Pv erythrocyte
infection in Duffy A+/A2 vs A+/A+ individuals in unmatched analyses
(p=0.026; log-rank test). B, Cumulative Pf erythrocyte infection in Duffy
A+/A2 vs A+/A+ individuals in unmatched analyses (p=0.875; log-rank
test).
doi:10.1371/journal.pone.0000336.g001
Pv in FY(-) Heterozygotes
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fluorescent signal intensity represents a 4-fold lower signal intensity
among heterozygous children. This reduction in parasitemia was
similar to that observed between younger (m=2.81) compared to
older A+/A+ individuals (m=2.25) (Mann-Whitney U: p,0.0001).
These results suggest that the A+/A2 genotype confers a level of
protection against Pv blood stage infection that would otherwise be
attributable to acquired Pv-specific immunity. Interestingly, this
difference in mean Pv parasitemia conferred by A+/A2 was no
longer observed in individuals over 15 years of age (m=2.22 in
A+/A+ vs. m=2.16 in A+/A2; Mann-Whitney U: p,0.86).
Finally, when these studies were performed following a real-time
quantitative PCR strategy to estimate Pv parasitemia, results
between molecular diagnostic strategies (LDR-FMA to RTQ-
PCR) were highly concordant (R
2=0.620, p,0.0001), and
comparisons between Pv susceptibility, Duffy genotype and age
were identical to those reported above. In an analysis of repeated
measures using generalized estimating equations to estimate the
impact of the Duffy genotype on the mean Pv fluorescent signal
intensity and adjust for Pf co-infection and correlations over time,
we found that children with the A+/A2 genotype had a 1.25-fold
lower mean Pv parasite density based on LDR-FMA than children
with the A+/A+ genotype (p=0.017). These findings are
consistent with our evaluations on infection prevalence and
infection intensity showing that a reduced risk of Pv blood-stage
infection was associated with the A+/A2 genotype.
Because some studies have suggested that Pv infection reduces
the severity of Pf infection, we were interested in determining
whether Duffy genotype influenced susceptibility to Pf blood stage
infection. In additional comparisons between children under and
15 years and older individuals (Figure 3B), we observed no
difference in the mean Pf fluorescent signal intensity between A+/
A+ and A+/A2 individuals (under 15 years–3.08 vs. 3.22, Mann-
Whitney-U: p=0.742; 15 years and older–2.51 vs. 2.69, Mann-
Whitney-U: p=0.648). Similar to results for Pv parasitemia, we
did observe that older individuals had lower Pf parasitemia than
younger individuals. Our results suggest, therefore, that while we
observed a reduction in Pv parasitemia in Duffy A+/A2 com-
pared to A+/A+ individuals, we did not observe that a reciprocal
increase in Pf parasitemia was associated with Duffy A+/A2.
Whether these results offer insight into events of human
evolution responsible for fixation of the Duffy B2 allele in African
populations would be difficult to substantiate. What is intriguing
about our observations in a region of PNG endemic for both Pv
and Pf is the juxtaposition between a significant reduction in Pv
risk in A+/A2 children and proposals that Pv infection reduces
severity of falciparum malaria [14,33–35,3]. If these proposals
were correct, we might expect that A+/A2 individuals would
Figure 2. Susceptibility to blood-stage infection during monthly prevalence surveys (1998–99); matched longitudinal analyses. Evaluation of
cumulative Pv and Pf erythrocyte infection was performed among Duffy A+/A2 vs A+/A+ individuals matched by age, sex, and village of residence. A,
Diagnosis of Pv erythrocyte infection was performed by light microscopy (LM) (p=0.049; log-rank test) [16]. B, Diagnosis of Pv erythrocyte infection
was performed by LDR-FMA (p=0.065; log-rank test) [20]. C, Diagnosis of Pf erythrocyte infection was performed by LM (p=0.675; log-rank test). D,
Diagnosis of Pf erythrocyte infection was performed by LDR-FMA (p=0.453; log-rank test). In A through D, light gray lines represent A+/A2 (n=11)
and dark gray lines represent A+/A+ (n=33).
doi:10.1371/journal.pone.0000336.g002
Pv in FY(-) Heterozygotes
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falciparum infection and therefore reduced fitness. In contrast to this
expectation the Duffy A2 allele has been consistently inherited over
at least four generations within the Wosera community, and the
frequency of this new PNG allele has risen above 6.5% within some
villages. These observations imply that Duffy A2 confers some
selective advantage within the population. As it is clear that vivax
malaria can cause significant morbidity [12,13], our observations in
the Wosera would suggest that A+/A2 heterozygosity may in some
way be protective against vivax-related mortality. While our data do
not rule out an increased risk of Pf illness in A+/A2 individuals, it is
reassuring that we did not detect any effect on risk of Pf infections
and density of Pf infections, given that risk and degree of malaria
illness is related to levels of parasitemia [36].
It is important to acknowledge that we have yet to identify
a homozygous Duffy negative (A2/A2) individual in PNG and,
based on a review of the Wosera Demographic Surveillance
database, we have not yet identified parental partners who are
both A+/A2 heterozygous. Thus, it is difficult to predict, based on
allele frequency, when we should expect to identify Duffy negative
individuals in the Wosera. This data alone, however, cannot be
used to rule out the possibility that the A2/A2 homozygous
genotype might be associated with significant negative fitness and
constrain the Duffy A2 allele to the role of a balanced polymor-
phism [37] in PNG.
When assessing the potential of Pv as a cause of human genetic
adaptation, it is important to remember that previous character-
ization of Pv as a ‘‘benign’’ human malaria parasite are based
upon data collected from adults receiving malaria therapy [38],
and may have little relevance to vivax malarial disease experienced
in children. Therefore, it will be important for future studies to
compare susceptibility to clinical malaria between Duffy A+/A2 vs.
A+/A individuals in relation to Pv and Pf, in single and mixed
speciesinfections.Ourresultsalsoprovidenewevidencethatlimiting
access of the Pv merozoite to the Duffy antigen will reduce
susceptibility to vivax blood-stage infection. Overall, as we do not
observe a significant increase in Pf parasitemia in the Duffy A+/A2
individualstested,ourobservationssuggestthateffortstodevelop Pv-
specific vaccines should be pursued, and emphasize that strategies to
target the Pv Duffy binding protein should be strongly considered.
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less than 15 years of age, A+/A+ (n=146) mean fluorescent signal intensity=3.08, A+/A2 (n=17) mean fluorescent signal intensity=3.22 (Mann-
Whitney P=0.742). For individuals over 15 years, A+/A+ (n=89) mean fluorescent signal intensity=2.51, A+/A2 (n=22) mean fluorescent signal
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